Table S2. Heterogeneity assessment of pairwise comparison

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Outcome | Pairwise comparison | Number of studies | *P* | I2 |
| ACR 20 | IFX *vs* PBO | 2 | 0.49 | 0% |
|  | APR *vs* PBO | 6 | 0.65 | 0% |
|  | ADA *vs* PBO | 4 | 0.01 | 73% |
|  | UST *vs* PBO | 3 | 0.35 | 5% |
|  | GOL *vs* PBO | 2 | 0.74 | 0% |
|  | ABA *vs* PBO | 2 | 0.58 | 0% |
|  | SEC *vs* PBO | 4 | 0.86 | 0% |
|  | ETN *vs* PBO | 2 | 0.13 | 57% |
|  | IXE *vs* PBO | 2 | 0.41 | 0% |
|  |  |  |  |  |
| PASI 75 | IFX *vs* PBO | 2 | 0.94 | 0% |
|  | APR *vs* PBO | 6 | 0.17 | 38% |
|  | ADA *vs* PBO | 3 | 0.04 | 68% |
|  | UST *vs* PBO | 2 | 0.52 | 0% |
|  | GOL *vs* PBO | 2 | 0.02 | 80% |
|  | ETN *vs* PBO | 2 | 0.08 | 68% |
|  | IXE *vs* PBO | 2 | 0.009 | 85% |
|  |  |  |  |  |
| SAE | IFX *vs* PBO | 2 | 0.8 | 0% |
|  | APR *vs* PBO | 6 | 0.5 | 0% |
|  | ADA *vs* PBO | 4 | 0.3 | 19% |
|  | UST *vs* PBO | 3 | 0.14 | 48% |
|  | GOL *vs* PBO | 2 | 0.03 | 79% |
|  | ABA *vs* PBO | 2 | 0.35 | 0% |
|  | SEC *vs* PBO | 4 | 0.44 | 0% |
|  | ETN *vs* PBO | 2 | 0.52 | 0% |
|  | IXE *vs* PBO | 2 | 0.58 | 0% |

Note: PBO, placebo; IFX, infliximab; APR, apremilast; ADA, adalimumab; TOF, tofacitinib; UST, ustekinumab; GOL, golimumab; ABA, abatacept; SEC, secukinumab; CZP, certolizumab pegol; BRD, brodalumab; ETN, etanercept; CLA, clazakizumab; IXE, ixekizumab; ABT, ABT-122.